InspireMD Inc (NSPR)
1.52
-0.02 (-1.30%)
USD |
NASDAQ |
Sep 26, 16:00
1.52
0.00 (0.00%)
After-Hours: 18:35
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 12.65M |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -64.43% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 2.292 |
| Price to Book Value | 0.4914 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.00 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 100.00% |
News
Headline
Wire
Time (ET)
Yahoo
09/13 16:05
NAMSA and InspireMD Announce Strategic Outsourcing Partnership to Accelerate New Product Development
Yahoo
09/08 09:00
Yahoo
08/09 07:00
Globe Newswire
08/09 07:00
Yahoo
08/02 08:00
Globe Newswire
08/02 08:00
Globe Newswire
07/14 08:00
Globe Newswire
06/09 08:00
Events
| DATE | TIME | TYPE | PERIOD | REPORTED EPS |
ESTIMATED EPS |
SURPRISE | |
| 11/09/2022* | -- | Results | Q3 2022 | -- | -0.73 | -- | |
| 11/09/2022* | 08:30 EST | Earnings Call | Q3 2022 | -- | -- | -- | |
| 11/09/2021 | -- | Results | Q3 2021 | -0.53 | -0.82 | 35.37% | |
| 11/09/2021 | 08:30 EST | Earnings Call | Q3 2021 | -- | -- | -- | |
| 08/10/2021 | -- | Results | Q2 2021 | -0.46 | -9.45 | 95.13% | |
| 08/10/2021 | 08:30 EST | Earnings Call | Q2 2021 | -- | -- | -- | |
| 05/11/2021 | -- | Results | Q1 2021 | -0.53 | -0.60 | 11.67% | |
| 05/11/2021 | 08:30 EST | Earnings Call | Q1 2021 | -- | -- | -- |
*Estimated Date/Time
Earnings
Profile
Edit
| InspireMD Inc is the United States based medical device company. It is focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. The products of the company are the CGuard carotid Embolic Prevention System (CGuard EPS) and the MGuard Prime Embolic Protection System (MGuard Prime EPS). It generates the majority of the revenue from the sales of CGuard EPS which combines MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. The group operates in Germany, Italy, Belarus, Brazil, and other countries. |
| URL | https://www.inspiremd.com |
| Investor Relations URL | http://www.inspiremd.com/en/investors/investor-relations/ |
| HQ State/Province | N/A |
| Sector | Healthcare |
| Industry | Medical Devices |
| Equity Style | Small Cap/Value |
| Next Earnings Release | Nov. 09, 2022 (est.) |
| Last Earnings Release | Nov. 09, 2021 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Dividends
| Dividend Per Share (TTM) | -- |
|
2017
2018
2019
2020
2021
6.00%
4.00%
2.00%
|
|
| Yield to Market | 0.00 |
| Yield to Sector | 0.00 |
| Yield to Industry | 0.00 |
| Last Dividend Amt. | -- |
| Dividend Frequency | -- |
| Last Ex-Dividend Date | -- |
| Yield (TTM) | 0% |
| Forward Yield | -- |
| Payout Ratio | 0.00% |
| Cash Payout Ratio | 0.00% |
| Consistent Payer (5Y) | No |
| Consistent Growth (5Y) | No |
Risk Info
Total Returns Comparison
Annual Total Returns Versus Peers
As of September 23, 2022.
Fundamentals
| Revenue (TTM) | 5.165M |
| Total Expenses (TTM) | 22.29M |
| Net Income (TTM) | -17.28M |
| Total Assets (Quarterly) | 32.77M |
| Total Liabilities (Quarterly) | 7.024M |
| Shareholders Equity (Quarterly) | 25.74M |
| Cash from Operations (TTM) | -14.28M |
| Cash from Investing (TTM) | -20.54M |
| Cash from Financing (TTM) | -0.072M |
Ratings
Profile
Edit
| InspireMD Inc is the United States based medical device company. It is focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. The products of the company are the CGuard carotid Embolic Prevention System (CGuard EPS) and the MGuard Prime Embolic Protection System (MGuard Prime EPS). It generates the majority of the revenue from the sales of CGuard EPS which combines MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. The group operates in Germany, Italy, Belarus, Brazil, and other countries. |
| URL | https://www.inspiremd.com |
| Investor Relations URL | http://www.inspiremd.com/en/investors/investor-relations/ |
| HQ State/Province | N/A |
| Sector | Healthcare |
| Industry | Medical Devices |
| Equity Style | Small Cap/Value |
| Next Earnings Release | Nov. 09, 2022 (est.) |
| Last Earnings Release | Nov. 09, 2021 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Risk Info
Ownership
| Insider Ownership Percentage | Upgrade |
Jul '20
Nov '20
Mar '21
80.00%
40.00%
10.00%
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Other Resources
| Whale Wisdom | 13F Filings |
| Seeking Alpha | Call Transcripts |
| Morningstar | Insider Trading |
| Nasdaq | Institutional Ownership |
| Nasdaq | Option Chain |
| SEC | SEC Filings |
| NSPR Tweets |